Abstract 357P
Background
Advanced Head and neck cancer despite multimodal treatment is associated with disfigurement, extreme pain, and psychological distress. To study the effects of a multimodal palliative approach involving psychological counselling, psychometric dug therapy and pain-relieving blocks to ameliorate the total pain state of such patient during end of life care.
Methods
This is a prospective, single-arm observational study conducted on 20 head and neck cancer patients, from January 2015 to December 2018. Patients who were on palliative treatment were processed for self-report of severe psychological distress and intractable pain by means of innovative distress score and quality of life index and the numeric pain rating scale and given combination therapy with antidepressants, antipsychotics, pain killers and neurolytic blocks along with repeated counselling sessions.
Results
20 patients were included in this study, of which 66.6 % were males and 33.3% were female. Age range was 44-79 years and they had mean pain scores of 7.61 (SD 1.577) before the intervention and mean distress scores of 8.33 (SD 1.237) suffering for a duration of 72.5 days (SD 24.81). A significant reduction in pain was noted by a decrease in mean Numeric rating scale to 2.83 (SD 0.618) and extension of the mean duration of analgesia to 24.33 days (SD 6.84) and reduction in distress score to 3.78 (SD 0.732). Pre- and post-procedure mean morphine requirement was also significantly reduced, at the end of 2 weeks. Significant easing of distress and improvement in performance was observed in all patients.
Conclusions
The application of a multimodal palliative approach to progressive head and neck cancer patients is an easy, safe, and cost-effective method to improve quality of life. Medical oncologists must be sensitized to elicit and measure the distress in such patients. Counseling sessions and pharmacotherapy, if indicated, are very effective in the care of such patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
241P - Impact of genomic alterations and HPV genotypes on clinical outcomes of Japanese patients with locally advanced cervical cancer
Presenter: Ikumi Kuno
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract